The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
<p>The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.</p>
Сохранить в:
| Главный автор: | Seyed Reza Mousavi (13223324) (author) |
|---|---|
| Другие авторы: | Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author) |
| Опубликовано: |
2025
|
| Предметы: | |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
Схожие документы
-
Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
по: Seyed Reza Mousavi (13223324)
Опубликовано: (2025) -
Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
по: Seyed Reza Mousavi (13223324)
Опубликовано: (2025) -
Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
по: Seyed Reza Mousavi (13223324)
Опубликовано: (2025) -
Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
по: Seyed Reza Mousavi (13223324)
Опубликовано: (2025) -
Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
по: Anna Starshinova (22571846)
Опубликовано: (2025)